title: [Immunotherapy with acarus extract in children under the age of 5 years].
abstract: BACKGROUND
  Specific immunotherapy with allergens is the only treatment capacite of modifying the natural course of allergic diseases. Although its effectiveness is higher when started in early stages, WHO guidelines still consider age under 5 years as relative contraindication.A review of a group of 22 children starting immunotherapy before the age of 5 years in a pediatric allergy unit was attempted to assess the effectiveness and safety of this treatment.
  
  
  RESULTS
  Clinical charts of 22 children with house dust mite asthma starting conventional immunotherapy before the age of 5 years were reviewed. In all cases, biologically standardized extracts and conventional subcutaneous schedules have been used and administration was performed in a hospital setting. Effectiveness and safety were evaluated by clinical scores. The average treatment period was 16.95 ( 10.12) months. Systemic reactions (moderate) were observed in 7 children and local reactions in 5. Children treated for more than 1 year (15 patients) showed a decrease in the number of yearly acute exacerbations (from 5.13 to 2.57) and in hospital admissions (from 5 to 2 children). In 10 patients, drug requirements for bronchial asthma were reduced.
  
  
  CONCLUSIONS
  The clinical data if this study suggest that house dust mite specific immunotherapy under hospital control can be begun in young children with good tolerance and clinical improvement.
authors.affiliation: Unidad de Alergia, Inmunología y Neumología Pediátrica, Hospital de Sabadell, Corporació Parc Taulí, Sabadell, Spain.
authors.forename: M J
authors.initials: MJ
authors.lastname: Paniagua
authors.forename: M
authors.initials: M
authors.lastname: Bosque
authors.forename: O
authors.initials: O
authors.lastname: Asensio
authors.forename: H
authors.initials: H
authors.lastname: Larramona
authors.forename: M T
authors.initials: MT
authors.lastname: Marco
mesh_terms: D000367:Age Factors; D000485:Allergens / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D002675:Child, Preschool; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous; D008297:Male; D008925:Mites / Q000737:chemistry*
chemical_list: D000485:Allergens